FY2029 Earnings Forecast for MNPR Issued By HC Wainwright

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of Monopar Therapeutics in a note issued to investors on Wednesday, January 22nd. HC Wainwright analyst S. Lee forecasts that the company will post earnings of $3.66 per share for the year. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09.

Several other brokerages have also commented on MNPR. Piper Sandler began coverage on Monopar Therapeutics in a report on Friday, January 10th. They set an “overweight” rating and a $72.00 price objective for the company. Rodman & Renshaw began coverage on Monopar Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $50.00 price objective for the company.

Monopar Therapeutics Trading Up 5.4 %

Shares of NASDAQ MNPR opened at $41.46 on Thursday. Monopar Therapeutics has a 12 month low of $1.54 and a 12 month high of $41.94. The firm has a market capitalization of $252.91 million, a price-to-earnings ratio of -21.05 and a beta of 1.23. The business has a 50-day moving average of $24.19 and a 200-day moving average of $12.34.

Insider Buying and Selling

In other news, CFO Karthik Radhakrishnan bought 1,550 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was bought at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the transaction, the chief financial officer now directly owns 1,550 shares of the company’s stock, valued at $25,187.50. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 34.90% of the stock is currently owned by corporate insiders.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.